These characteristics of the Sputnik V vaccine make it very effective, know everything about the new vaccine


Posted on 13th Apr 2021 04:28 pm by rohit kumar

In India, the Russian-developed Corona Vaccine Sputnik V has been approved for emergency use. This is the third vaccine for the coronavirus to be approved after Kovshield (Serum Institute of India) and Kovaxin (Bharat Biotech).

 

The Sputnik V vaccine, developed by Moscow's Gamale National Research Institute of Epidemiology and Microbiology, uses two different viruses that cause the common cold (adenovirus) in humans. Adenovirus becomes weak so it cannot replicate in humans and cannot cause disease.

 

Let me tell you that this vaccine is also modified. For this reason, the vaccine provides a code for making the coronavirus spike protein. The purpose of this process is to ensure that when the actual virus tries to infect the body, it can mount an immune response in the form of antibodies.

 

Sputnik uses a different vector for each of the two shots during vaccination. According to this Russian Direct Investment Fund (RDIF), the same methods are used for both shots. It provides immunity with a longer duration than other vaccines. A difference of 21 days is required for both shots.

 

Sputnik V (liquid) is stored at a temperature of minus 18 ° C. However, its dried form can be stored at 2–8 ° C. This does not require investing in cold-chain infrastructure. According to the RDIF, Sputnik V has been approved for the use of more than 150 crore people in 55 countries. The vaccine is proposed to be priced below $ 10 per shot. Although its price in India has not been decided.

 

Dr. Reddy's labs based in Hyderabad sought government approval for the vaccine in India. RDIF partnered with Dr. Reddy's in September 2020 to conduct clinical trials in the country. On Monday, the Subject Expert Committee (SEC) of the Drugs Controller General of India took the Sputnik V application for Emergency Use Authority and moved on. DCGI previously sought additional data from the drug manufacturer.

 

Five other Indian companies have partnered with RDIF for Sputnik V. These include Gland Pharma, Hetero Biopharma, Virchow Biotech, Panacea Biotech, and Stellis Biopharma, Bangalore-based Strides Pharma Science's bioceramic. It is expected from their partnerships that India's capacity to manufacture this vaccine will exceed 60 million.

1 Like 0 Dislike
Previous news Next news
Other news

Angry Workers vandalise Factories in Gurgaon

Gurgaon, Feb 12 (IANS) An angry mob of 5,000 workers Thursday vandalised offices of more than a

Let the 'Most Capable' win: Maken

New Delhi, Feb 7 (IANS) "May the most capable ones win," Congress leader Ajay Maken said Saturda

Will focus on Job Creation: Modi on Three-Nation Trip

New Delhi, March 28 (IANS) Prime Minister Narendra Modi said on Saturday the "primary objective

Kejriwal to undergo naturopathy for diabetes

Bengaluru, March 3 (IANS) Delhi Chief Minister Arvind Kej

India should realize potential of soft power: Modi

New Delhi, Feb 23 (IANS) Prime Minister Narendra Modi Monday said it was time for India to "rea

Sign up to write
Sign up now if you have flare of writing..
Login   |   Register
Follow Us
Indyaspeak @ Facebook Indyaspeak @ Twitter Indyaspeak @ Pinterest RSS



Play Free Quiz and Win Cash